These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

275 related items for PubMed ID: 17262062

  • 1. Autologous stem cell transplantation is safe and feasible in elderly patients with multiple myeloma.
    Qazilbash MH, Saliba RM, Hosing C, Mendoza F, Qureshi SR, Weber DM, Wang M, Flosser T, Couriel DR, De Lima M, Kebriaei P, Popat U, Alousi AM, Champlin RE, Giralt SA.
    Bone Marrow Transplant; 2007 Mar; 39(5):279-83. PubMed ID: 17262062
    [Abstract] [Full Text] [Related]

  • 2. Combined submyeloablative and myeloablative dose intense melphalan results in satisfactory responses with acceptable toxicity in patients with multiple myeloma.
    Novitzky N, Thomson J, Thomas V, du Toit C, Mohamed Z, McDonald A.
    Biol Blood Marrow Transplant; 2010 Oct; 16(10):1402-10. PubMed ID: 20385248
    [Abstract] [Full Text] [Related]

  • 3. High-dose therapy and autologous peripheral blood stem cells transplantation followed by a very low reduced intensity regimen with fludarabine + cyclophosphamide and allograft improve complete remission rate in de novo multiple myeloma patients.
    Martino M, Console G, Irrera G, Praticò G, Stelitano C, Callea V, Morabito F, Quartarone E, Musolino C, Piro E, Brugiatelli M, Iacopino P.
    Am J Hematol; 2006 Dec; 81(12):973-8. PubMed ID: 16888786
    [Abstract] [Full Text] [Related]

  • 4. Autologous stem cell transplantation in multiple myeloma: improved survival in nonsecretory multiple myeloma but lack of influence of age, status at transplant, previous treatment and conditioning regimen. A single-centre experience in 127 patients.
    Terpos E, Apperley JF, Samson D, Giles C, Crawley C, Kanfer E, Olavarria E, Goldman JM, Rahemtulla A.
    Bone Marrow Transplant; 2003 Feb; 31(3):163-70. PubMed ID: 12621476
    [Abstract] [Full Text] [Related]

  • 5. Complete remission status before autologous stem cell transplantation is an important prognostic factor in patients with multiple myeloma undergoing upfront single autologous transplantation.
    Kim JS, Kim K, Cheong JW, Min YH, Suh C, Kim H, Jo DY, Ryoo HM, Yoon SS, Lee JH, Korean Multiple Myeloma Working Party.
    Biol Blood Marrow Transplant; 2009 Apr; 15(4):463-70. PubMed ID: 19285634
    [Abstract] [Full Text] [Related]

  • 6. Long-term outcome of myeloablative allogeneic stem cell transplantation for multiple myeloma.
    Kuruvilla J, Shepherd JD, Sutherland HJ, Nevill TJ, Nitta J, Le A, Forrest DL, Hogge DE, Lavoie JC, Nantel SH, Toze CL, Smith CA, Barnett MJ, Song KW.
    Biol Blood Marrow Transplant; 2007 Aug; 13(8):925-31. PubMed ID: 17640596
    [Abstract] [Full Text] [Related]

  • 7. Veno-occlusive disease of the liver after high-dose cytoreductive therapy with busulfan and melphalan for autologous blood stem cell transplantation in multiple myeloma patients.
    Carreras E, Rosiñol L, Terol MJ, Alegre A, de Arriba F, García-Laraña J, Bello JL, García R, León A, Martínez R, Peñarrubia MJ, Poderós C, Ribas P, Ribera JM, San Miguel J, Bladé J, Lahuerta JJ, Spanish Myeloma Group/PETHEMA.
    Biol Blood Marrow Transplant; 2007 Dec; 13(12):1448-54. PubMed ID: 18022574
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Higher infused lymphocyte dose predicts higher lymphocyte recovery, which in turn, predicts superior overall survival following autologous hematopoietic stem cell transplantation for multiple myeloma.
    Hiwase DK, Hiwase S, Bailey M, Bollard G, Schwarer AP.
    Biol Blood Marrow Transplant; 2008 Jan; 14(1):116-24. PubMed ID: 18158968
    [Abstract] [Full Text] [Related]

  • 10. ThaDD plus high dose therapy and autologous stem cell transplantation does not appear superior to ThaDD plus maintenance in elderly patients with de novo multiple myeloma.
    Offidani M, Leoni P, Corvatta L, Polloni C, Gentili S, Savini A, Alesiani F, Brunori M, Catarini M, Visani G, Samori A, Burattini M, Centurioni R, Montanari M, Fraticelli P, Ruggieri M, Falcioni S, Galieni P.
    Eur J Haematol; 2010 Jun; 84(6):474-83. PubMed ID: 20331733
    [Abstract] [Full Text] [Related]

  • 11. Autologous stem cell transplantation in patients of 70 years and older with multiple myeloma: Results from a matched pair analysis.
    Kumar SK, Dingli D, Lacy MQ, Dispenzieri A, Hayman SR, Buadi FK, Rajkumar SV, Litzow MR, Gertz MA.
    Am J Hematol; 2008 Aug; 83(8):614-7. PubMed ID: 18429054
    [Abstract] [Full Text] [Related]

  • 12. Deletion of the short arm of chromosome 1 (del 1p) is a strong predictor of poor outcome in myeloma patients undergoing an autotransplant.
    Qazilbash MH, Saliba RM, Ahmed B, Parikh G, Mendoza F, Ashraf N, Hosing C, Flosser T, Weber DM, Wang M, Couriel DR, Popat U, Kebriaei P, Alousi AM, Anderlini P, Naeem RC, Champlin RE, Giralt SA.
    Biol Blood Marrow Transplant; 2007 Sep; 13(9):1066-72. PubMed ID: 17697969
    [Abstract] [Full Text] [Related]

  • 13. High-dose busulfan and melphalan as conditioning regimen for autologous peripheral blood progenitor cell transplantation in high-risk ewing sarcoma patients: a long-term follow-up single-center study.
    Diaz MA, Lassaletta A, Perez A, Sevilla J, Madero L, Gonzalez-Vicent M.
    Pediatr Hematol Oncol; 2010 May; 27(4):272-82. PubMed ID: 20426518
    [Abstract] [Full Text] [Related]

  • 14. High-dose therapy and autologous blood stem-cell transplantation compared with conventional treatment in myeloma patients aged 55 to 65 years: long-term results of a randomized control trial from the Group Myelome-Autogreffe.
    Fermand JP, Katsahian S, Divine M, Leblond V, Dreyfus F, Macro M, Arnulf B, Royer B, Mariette X, Pertuiset E, Belanger C, Janvier M, Chevret S, Brouet JC, Ravaud P, Group Myelome-Autogreffe.
    J Clin Oncol; 2005 Dec 20; 23(36):9227-33. PubMed ID: 16275936
    [Abstract] [Full Text] [Related]

  • 15. High-dose melphalan (200 mg/m2) supported by autologous stem cell transplantation is safe and effective in elderly (>or=65 years) myeloma patients: comparison with younger patients treated on the same protocol.
    Jantunen E, Kuittinen T, Penttilä K, Lehtonen P, Mahlamäki E, Nousiainen T.
    Bone Marrow Transplant; 2006 May 20; 37(10):917-22. PubMed ID: 16670701
    [Abstract] [Full Text] [Related]

  • 16. Prolonged overall survival with second on-demand autologous transplant in multiple myeloma.
    Elice F, Raimondi R, Tosetto A, D'Emilio A, Di Bona E, Piccin A, Rodeghiero F.
    Am J Hematol; 2006 Jun 20; 81(6):426-31. PubMed ID: 16680735
    [Abstract] [Full Text] [Related]

  • 17. Predictive factors for survival in myeloma patients who undergo autologous stem cell transplantation: a single-centre experience in 211 patients.
    O'Shea D, Giles C, Terpos E, Perz J, Politou M, Sana V, Naresh K, Lampert I, Samson D, Narat S, Kanfer E, Olavarria E, Apperley JF, Rahemtulla A.
    Bone Marrow Transplant; 2006 Apr 20; 37(8):731-7. PubMed ID: 16501593
    [Abstract] [Full Text] [Related]

  • 18. Intravenous melphalan, thalidomide and prednisone in refractory and relapsed multiple myeloma.
    Palumbo A, Avonto I, Bruno B, Ambrosini MT, Bringhen S, Cavallo F, Falco P, Boccadoro M.
    Eur J Haematol; 2006 Apr 20; 76(4):273-7. PubMed ID: 16519697
    [Abstract] [Full Text] [Related]

  • 19. Comparison of high-dose melphalan with a more intensive regimen of thiotepa, busulfan, and cyclophosphamide for patients with multiple myeloma.
    Anagnostopoulos A, Aleman A, Ayers G, Donato M, Champlin R, Weber D, Alexanian R, Giralt S.
    Cancer; 2004 Jun 15; 100(12):2607-12. PubMed ID: 15197803
    [Abstract] [Full Text] [Related]

  • 20. Alpha-interferon maintenance treatment is associated with improved survival after high-dose treatment and autologous stem cell transplantation in patients with multiple myeloma: a retrospective registry study from the European Group for Blood and Marrow Transplantation (EBMT).
    Björkstrand B, Svensson H, Goldschmidt H, Ljungman P, Apperley J, Mandelli F, Marcus R, Boogaerts M, Alegre A, Remes K, Cornelissen JJ, Bladé J, Lenhoff S, Iriondo A, Carlson K, Volin L, Littlewood T, Goldstone AH, San Miguel J, Schattenberg A, Gahrton G.
    Bone Marrow Transplant; 2001 Mar 15; 27(5):511-5. PubMed ID: 11313685
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.